Thyroid Eye Disease

Graves’ orbitopathy, also known as thyroid eye disease (TED), is an autoimmune condition in which immune cells attack the thyroid gland, which in turn responds by secreting an excess amount of thyroid hormone. As a result, the thyroid gland enlarges and excess hormones change metabolism and affect the function of the heart, brain and other organs. The hyperthyroid state is characterized by fast pulse/heartbeat, palpitations, increased sweating, high blood pressure, irritability, fatigue, weight loss, heat intolerance, and loss of hair and alterations in hair quality. At times, people in the hyperthyroid state can be diagnosed with a psychiatric disorder, such as bipolar or manic disorder, while in fact they have a side effect of hyperthyroidism.

The eyes are particularly vulnerable to thyroid disease, because the immune system that attacks the thyroid gland often also targets the eye muscles and connective tissue within the eye socket (orbit). The skin is also affected, but to a lesser degree in most patients. The immunologic attack on the tissues of the orbit results in scarring of the orbital tissues, enlargement of the eye muscles, and expansion of the fat compartment that is present to protect the eye. The exact trigger for thyroid eye disease is not known, but the orbital tissues likely share some antigenic features with the thyroid gland. In addition, the orbital tissues contain receptors and enzymes that respond to changes in thyroid hormone levels. Eye symptoms can range from mild to severe, but only 10-20% of patients have vision-threatening disease.

Thyroid eye disease can also be present when the level of thyroid hormone in the blood is normal or low, depending on the degree of glandular stimulation caused by the immune attack and by the amount of thyroid gland destruction present at the time of diagnosis. However, most patients with eye symptoms have abnormal hormone levels that are accompanied by specific antibodies in the blood stream. The components of the disease affecting the thyroid gland versus the eyes have common causes, but evolve separately and must each be treated separately.

  • Swelling (edema) of the eyelids and tissue around the eye
  • A constant stare
  • Eyelid retraction
  • Dry eyes or a sensation of grit or irritation to the eye
  • Watering and redness of the eyes
  • Sensitivity to light
  • A feeling of pressure in the eye sockets
  • Double vision
  • Loss of vision
  • Loss of perception of bright colors (especially red color becomes grayish)

The symptoms described above may not necessarily mean that a person has thyroid eye disease. However, if you experience these symptoms, contact your eye doctor for a complete examination to evaluate for this common eye condition.

When the immune system attacks the muscles and other ocular tissues in the eye socket, the swelling and scarring resulting from the inflammation can cause the symptoms and signs noted above. In severe cases, the transparent window of the eye (cornea) may ulcerate, or the optic nerve may be damaged, either of which may result in a permanent loss of vision if not treated appropriately. Corneal damage is often due to a combination of the eyes bulging forward and eyelid retraction from eyelid tissue scarring, leading to exposure of the cornea from poor lid closure (see below). Optic nerve damage is due to thickened, inflamed and/or scarred muscles impinging on the optic nerve at the back of the socket (apex), just as the nerve exits the orbit to enter the brain (see below).

In most patients who develop Graves’ ophthalmopathy, the eyes bulge forward or the eyelid retracts to some degree. Many patients with mild to moderate Graves’ ophthalmopathy will experience spontaneous improvement over the course of two to three years or will adapt to the abnormality and learn to compensate. Severe ophthalmopathy will affect approximately 10% of patients. It is caused by inflammation of the muscles, which causes them to swell. As they swell, the muscles can scar in the swollen state, push the eye forward, and press on the nerve in the orbital apex. Scarring of the muscles can lead to double vision and even compression of the optic nerve, causing loss of vision. In some patients, eye protrusion makes it difficult for the lids to close properly and the cornea becomes exposed and vulnerable. When the optic nerve is compromised, progressive and irreversible vision loss can occur. Rarely, orbital swelling may precipitate glaucoma that can also affect the optic nerve. Surgical intervention is often required in order to save or restore adequate visual function.

Approximately one million Americans are diagnosed with Graves’ disease each year. Women are much more likely than men to get Graves’ disease, but both men and women can develop thyroid eye disease. Cigarette smokers are at significantly increased risk to develop the eye disease, and when they do, often have more severe and prolonged activity that threatens vision. Patients who have vitamin D deficiency are more likely to develop thyroid eye disease. Furthermore, treatment with radioactive iodine, unstable thyroid hormone levels, and/or high levels of anti-thyroid antibodies, are all important risk factors for the development of thyroid eye disease.

If your doctor suspects you have an overactive or underactive thyroid gland, your thyroid function must first be evaluated and treated appropriately by an internist trained in doing so. Treatments include medications to suppress the production of hormone by the thyroid gland, radioactive iodine to eliminate hormone-producing cells, and surgery to remove the thyroid tissue. In most cases, replacement thyroid hormone is required following the natural course of the Graves’ autoimmune attack on the thyroid gland or following effective treatment. Once your thyroid function is treated and returned to normal, the eye disease must be monitored as it often continues to progress. Eye involvement must be evaluated on a continuing basis by an ophthalmologist during the active phase of the disease and, if necessary, treated. Although symptoms often resolve on their own, activity, scarring, and visual loss not readily apparent to the patient may otherwise go unnoticed and cause permanent changes.

Treatment for thyroid eye disease generally occurs in two phases. The first phase involves treating the active eye disease. This active period can last from a few months to as many as three years. Smoking lengthens the period of activity. Treatment during the active phase of the disease focuses on preserving sight and the integrity of the cornea as well as providing treatment for double vision when it interferes with daily functioning and becomes bothersome.

Most patients experience relief from dry eyes by using artificial tears throughout the day and gels or ointments at night. Some patients also use eye covers at night or tape their eyes shut to keep them from becoming dry if the eyelids do not close properly. Dryness occurs because the lids are retracted and cannot blink properly, because the tear-producing glands have been affected by the autoimmune process and aren’t functioning well, and/or because the forward bulging of the eyes prevents them from being completely covered by the lids. In some cases, acute swelling causing double vision or loss of vision may be treated for a limited time with oral prednisone. However, prednisone given for more than a few weeks at the dosages required to suppress the autoimmune inflammation always causes bothersome and dangerous side-effects that may become severe. In patients who respond to prednisone, a short course of intravenous (IV) steroids (methylprednisolone) may provide symptomatic improvement with fewer side effects than oral prednisone; this is referred to as an IV steroid pulse. Surgical decompression can also be used during the active phase, most often to relieve progressive damage to the optic nerve (optic neuropathy), but sometimes it can also helpful in reducing orbital congestion, redness, pain, and eye exposure.

A newly FDA-approved drug, teprotumumab (Tepezza®, Horizon Therapeutics), has been shown to be effective in the majority of patients with active thyroid eye disease, i.e. patients who experience eye redness, pain with eye movement, worsening proptosis, and/or worsening diplopia. Teprotumumab is given by eight IV infusions over 24 weeks. It is very expensive, and requires insurance pre-authorization, but can be a very good option for some patients.

Once the disease achieves remission and the thyroid hormone levels are stabilized, treatment can focus on restoring function and correcting unacceptable changes that persist after the ocular conditions of the active phase have stabilized, such as bulging eyes (proptosis), double vision (diplopia), and eyelid malposition. Treatment at this point is typically surgical, and needs to proceed in a predetermined order: orbital surgery first to correct the proptosis (orbital decompression), followed by eye muscle surgery to correct the diplopia, followed by eyelid surgery to improve eyelid closure and corneal protection.

It is critically important to stop smoking in order to reduce the severity and duration of thyroid eye disease!

Thyroid Eye Disease Surgical Management

Surgical management of thyroid eye disease (TED) follows a sequence that is tailored to patient needs. The key issues addressed by surgery include proptosis, orbital pressure/pain, orbital inflammatory signs, diplopia secondary to restrictive strabismus, ocular surface exposure secondary to lagophthalmos, and eyelid retraction. These are traditionally addressed sequentially by orbital decompression, strabismus surgery, and eyelid retraction repair surgery. The extent of surgical rehabilitation is patient specific and customized to the needs of each patient. Coordination and proper sequencing of surgical intervention is key to promoting good outcomes. In this chapter, we focus primarily on orbital decompression and eyelid surgery – the two main reconstructive surgeries performed by oculoplastic surgeons for patients with TED.

Orbital decompression surgery is performed to address the tight compartment caused by expansion of orbital soft tissues. The surgery essentially rebalances the contents to the size of the bony orbit, thereby reducing orbital pressure, proptosis, and, when present, compressive optic neuropathy. Surgical techniques include different approaches to removing orbital bone in order to enlarge the space within the orbital compartment, as well as removal of scarred fat and connective tissue to reduce the volume of orbital soft tissue.

Strabismus surgery is performed following orbital decompression surgery, but prior to eyelid retraction surgery. This is done for three reasons: (1) orbital decompression must be performed first because it can alter mechanical vectors of extraocular muscle function, leading to changes in eye alignment, (2) restrictive strabismus can lead to secondary eyelid retraction – essentially a pseudoretraction that can be reduced by releasing the extraocular muscle restriction, and (3) strabismus surgery can itself cause eyelid retraction – particularly of the lower eyelids – secondary to the relationship of the lower eyelid retractors to the inferior rectus and oblique muscles.

It is important to note that for patients with double vision who require strabismus surgery, recession of fibrotic inelastic muscles frequently causes worsening proptosis. Therefore, it is important to provide sufficient decompression to account for the expected increase in proptosis following strabismus surgery, and to properly counsel patients.

Eyelid retraction repair is performed last – once proptosis is reduced to an acceptable level, any compressive issues are addressed, and strabismus is resolved. Upper eyelid retraction repair typically requires release of eyelid retractors, which undergo fibrosis as part of the orbitopathy process. This can be done via anterior or posterior surgical approaches, and may involve levator muscle, Müller’s muscle, and/or conjunctiva. Lower eyelid retraction repair frequently requires a spacer graft, which can be autologous (e.g. hard palate, ear cartilage, dermis), allograft or xenograft (e.g. decellularized dermis), or alloplastic material.

Here we will describe the diagnostic process for customizing a surgical plan, perioperative planning, surgical techniques and post-operative considerations.

TED can manifest with proptosis secondary to expansion of fat, seen as dark areas around the eye muscles

Figure: TED can manifest with proptosis secondary to expansion of fat, seen as dark areas around the eye muscles (left image) or secondary to thickening of the eye muscles (right image).

The most common surgical approaches to orbital decompression surgery include: (1) lateral decompression through an extended lateral upper eyelid crease or a lateral canthotomy approach to the lateral orbit, lateral roof and lateral floor (avoiding injury to the lateral commissure); (2) medial transconjunctival approach to the orbit (allows access to the medial orbit and posterior floor); and (3) inferior fornix approach to the anterior floor and orbital fat. Endonasal surgery is a reasonable option to access the medial wall and floor, although this approach has several important limitations, including extended length of surgery, removal of tissue while moving toward the globe instead of away from the globe (increasing risk of inadvertent injury), and a more limited access to the orbital process of the palatine bone at the orbital apex1.

With improved techniques and better fellowship training, the trend in surgical decompression has been toward more nuanced customizable techniques that enhance outcomes and decrease morbidity. Dr. Kahana has been a leader in developing customizable minimally-invasive surgical approaches to orbital decompression. Each surgery for TED is individually tailored based on patient characteristics and surgeon experience. The goal of surgery is to expand the posterior bony part of the orbit in order to accommodate the fibrotic, thickened muscles while removing abnormal, scarred fat that occupies too much space in the orbit, which pushes the eye forward. Importantly, improved understanding of how to deeply contour the diploic spaces within the sphenoid, frontal and zygomatic bones have led to excellent results with dramatic improvements in proptosis reduction through smaller incisions and without damaging the lateral orbital rim.

Customization of orbital decompression can be accomplished through the number and choice of orbital walls removed, augmenting the decompression with excision of hypertrophied and fibrotic orbital fat, varying the extent of ethmoidectomy (medial decompression) or deep bone removal (lateral decompression), targeting the posterior inferomedial strut and orbital process of the palatine bone, and timing of surgery. The development of modern techniques has been made possible by advancements in noninvasive imaging, preoperative analysis of the orbital anatomy, stereotactic image-guided surgical navigation devices, Piezoelectric technology that minimizes tissue damage, and an improved understanding of the spectrum of orbital pathology represented by thyroid eye disease (TED).

The surgeons at Kahana Oculoplastic and Orbital Surgery utilize ultrasonic aspiration through small incisions to remove bone just where it needs to be removed, minimizing the risk of damage to other parts of the orbit. Frequently, surgery is performed using stereotactic navigation. Dr. Kahana’s research has shown that stereotactic navigation facilitates the small incision approach and actually improves surgical outcomes by improving proptosis reduction and reducing the rates of post-operative strabismus.

The acute phase of TED is marked by congestive and inflammatory signs, such as chemosis, caruncular edema, eyelid edema, orbital pain and progressive strabismus. For many years, conventional wisdom ruled that orbital decompression should be avoided in patients in the acute phase of TED, limiting treatment to medical measures, including topical lubrication, salt restriction, head elevation, prism glasses, corticosteroids (oral, intravenous or intraorbital), and low-dose external beam radiotherapy. Details of medical therapy, including new potential therapeutic modalities, are described in a different resource. However, with the understanding that congestion and inflammation cannot be differentiated based on clinical exam, and the further understanding that orbital congestion leads to venous stasis and accumulation of cytokines within the orbit, our surgeons can perform orbital decompression surgery for orbits with acute-phase signs and symptoms – with excellent results.

TED with imminent visual threat due to dysthyroid compressive optic neuropathy (CON) occurs in approximately 6% of patients and represents a unique, more urgent situation. These orbits will typically require decompression surgery, with the urgency determined by the clinical exam findings. Importantly, unlike other causes of optic neuropathy, such as microvascular disease, visual field loss from CON is often reversible, revealing a unique resilience in retinal ganglion cells and axons that may have to do with axonal stasis. Still, that resilience should not be tested without important medical reasons, and orbital decompression is often required at the earliest opportunity for optimal outcomes.

In patients whose vision is not acutely threatened, the decision regarding when to perform orbital decompression is more nuanced. A single pulse of intravenous corticosteroids may serve as a therapeutic trial that can differentiate the inflammatory and congestive processes in the acute phase: inflammatory orbitopathy improves following corticosteroid administration, while congestive orbitopathy is usually unresponsive. Early orbital decompression may have beneficial effects on the overall course of the orbitopathy by relieving the orbital congestion and improving blood flow to orbital tissues in patients with symptomatic orbital congestion. Hence, orbital decompression surgery is no longer relegated to a rehabilitative stage once the disease has become quiescent, but is rather considered a key stage of a multi-step approach to control TED and avoid its more significant consequences. Since its approval by the FDA, teprotumumab (Tepezza®, Horizon Therapeutics) has become another option for patients with active disease and orbital congestion, in addition to or as an alternative to orbital surgery. Studies have revealed that 60-80% of patients have some response to 24 weeks of teprotumumab infusions, and at least half of these patients have a sustained response.

Although early decompression may be beneficial, orbital decompression surgery should not be undertaken prior to the stabilization of endocrine disease. Conventional wisdom is that the thyroid status is not directly related to the orbit. Our clinical experience, and an extensive nuanced reading of the literature, have revealed that this is not necessarily true. In particular, we have found that in patients who have successfully ceased smoking and whose thyroid function tests are stable prior to (and following) decompression, a primary decompression is frequently successful, with rare need for additional decompressions at a later date. Thus, to obtain the best surgical result, the patient’s endocrine status needs to be normal and stable. Furthermore, the presence of TED is a contraindication for RAI therapy, which may provoke a recurrence or worsening of the orbitopathy.

For fat-predominant TED, excision of scarred fat is a primary mode of orbital decompression, usually accompanied by a limited removal of bone. On the other hand, for TED associated with scarred, thickened muscles, removal of bone is the primary tool for decompression, with excision of scarred fat serving as an adjunct to improve outcomes.

Importantly, in patients with thick, fibrotic muscles, especially those with limited eye movement, even an excellent decompression may not reduce proptosis all that much because of the stiff EOMs resisting the posterior repositioning of the globe within a decompressed orbit. Hence, proptosis reduction is only one variable when assessing outcomes of orbital decompression surgery, with other variables that include conjunctival chemosis and orbital pressure pain, both of which assess improvement in orbital congestion. Both lateral and medial decompression can achieve a good decompression of the orbital apex.

Because the optic foramen is located within the lesser wing of the sphenoid at the posterior edge of the medial wall, a posterior medial decompression has historically been thought to be the most effective approach to treating CON. However, it has been demonstrated that a full lateral decompression with deep bone removal can be just as effective in treating CON as a medial decompression.

Removal of bone is achieved using instruments that carve, contour and suction bony tissue using either ultrasonic or rotational power. The surgeons of Kahana Oculoplasitc and Orbital Surgery utilize an ultrasonic bone aspirator (Sonopet®, Stryker Corp.) for deep bone removal.

In lateral orbital decompression, once the trigone is exposed, bone removal is performed through the anterior cortical bone to expose the diploic space, which is filled with cancellous bone. Bone removal continues through the diploe, while every effort is made to avoid exposure of dura mater – the lining of the brain. To achieve a maximal decompression, the diploic space should be removed entirely to expose the inner cortical table of bone covering the temporal lobe posteriorly and the frontal lobe superiorly. In addition to the sphenoid and frontal trigones, significant bone removal can be accomplished along the inferior orbital fissure and extend to the inferolateral orbital floor. Occasionally, the roof of the maxillary sinus may be exposed. Superolaterally, the bone above the lacrimal gland fossa can also be removed.

Photos from tiny camera of TED

Figure: Intraoperative view before (left image) and after (right image) decompression of the lateral orbital wall. In the right image, the lateral wall has been contoured to allow for increased orbital volume into which the orbital contents can expand. Note the large amount of additional space that has been afforded for holding the orbital contents.

Figure: Coronal (A-C) and axial (D) CT orbits following medial and lateral orbital decompressions in a single patient.

Decompression of the orbital floor, whether directly or through inferior extension of a lateral decompression, can lead to inferior globe displacement. The combination of posterior and inferior displacement of the globe has the secondary effect of reducing lower eyelid retraction while increasing upper eyelid retraction, and can be customized to patients needs and overall surgical plan.

Adjunctive fat excision can now be performed, with excellent access to both inferolateral and superolateral fat compartments, and with good effect on both proptosis and lower eyelid contour/fullness.

Figure: Postoperative axial (upper row) and coronal (lower row) CT scans following a RIGHT lateral orbital decompression demonstrating increased orbital volume for soft tissue herniation.

The medial transconjunctival approach to orbital decompression facilitates access to the medial and posterior orbital bones to enable decompression without a skin incision. The surgery also includes opening the sinuses and removing any diseased sinus air cells in order to create additional space for orbital tissues to expand into. An important consideration of medial orbital decompression is strabismus, as this technique has been known to be associated with greater degree of induced strabismus. However, Kahana Oculoplastic and Orbital Surgery surgeons have perfected the technique to minimize the risk of induced strabismus and double vision (diplopia). Additional decompression can be achieved at the orbital apex by removing the posterior-most part of the orbital floor – a very effect and safe technique to decompress the optic nerve.

Once the bony decompression is completed, the periorbita is opened sharply with scissors or a sickle blade to allow for soft tissue herniation into the newly created space.

Figure: Intraoperative view of medial orbital decompression. a) The medial orbital wall is exposed. b) The frontoethmoidal suture, demarcated by the anterior and posterior ethmoidal foramina, identifies the superior boundary of planned decompression.

Figure: Medial orbital decompression. The medial orbital wall is exposed and debulked, taking care to not surpass the anterior boundary of decompression at the level of the anterior ethmoid foramen.

Following orbital decompression surgery, patients are prescribed oral analgesic medication and cold compresses for 3-5 days, along with the usual regimen of incisional care including an antibiotic ointment. They should be instructed to avoid exertion, bending, or lifting for at least 2-3 days post-operatively – the key time period for post-operative bleeding. Following surgery in the sinuses, nasal saline spray can be prescribed to facilitate healing and reduce post-operative congestive symptoms.

As with any surgery, orbital decompression can be associated with potential complications. The most important and common risks include infection, worsened strabismus/diplopia, and post-operative hemorrhage causing an acute compartment syndrome. Temporary postoperative hypoesthesia (numbness) has been reported in up to 29% of lateral decompressions and 17% of other bony decompressions. Diligent follow up of patients in the postoperative period is critical in order to detect potential complications and monitor healing.

Extraocular muscle surgery for TED is routinely performed by a strabismus specialist – pediatric ophthalmologist or neuro-ophthalmologist – to address ocular misalignment and any associated diplopia. Ocular misalignment may be affected by orbital decompression surgery – positively or negatively. Hence, patients who need orbital decompression should undergo that procedure prior to any strabismus surgery. Ideally, the orbital and strabismus surgery teams work closely together to optimize outcomes through proper sequencing and timing of surgeries. When available, orthoptic examinations before and after decompression surgery can provide useful information for planning eventual strabismus surgery.

In the past, conventional wisdom dictated that strabismus surgery should be delayed at least 6 months after decompression surgery. However, with improved coordination between orbital and strabismus surgeons and the more modern surgical techniques for orbital decompression, strabismus surgery may be performed as early as 6-8 weeks after decompression surgery, with good results as long as measurements are stable post-operatively.

Once a patient is ready for strabismus surgery, muscle recession is usually performed in TED to weaken the action of fibrotic muscles. The most commonly affected muscles are the inferior and medial rectus muscles, and these are often the targets of muscle recession surgery. Restrictive EOM disease can be challenging to treat since the altered muscles may not respond to surgery in a predictable fashion. Additionally, recessing fibrotic muscles nearly always worsens proptosis and/or lower eyelid retraction.

Optimal outcomes for strabismus surgery necessitate stability in ocular alignment measurements as documented over time. Since patients who smoke often have a less stable disease course, achieving optimal alignment in smokers with TED may be impossible. Patients should therefore be strongly encouraged to cease smoking prior to initiation of surgical rehabilitation.

An important consideration is the effect of strabismus surgery on eyelid position. In patients with a restricted inferior rectus muscle, attempting to bring the eye to primary position results in secondary upper eyelid retraction. Such retraction is improved following inferior rectus recession. However, recessing the inferior rectus can worsen lower eyelid retraction.

While many surgical techniques for eyelid reconstruction can be employed, the role of a good decompression in improving eyelid position is important. An effective decompression can reduce axial proptosis and sometimes reduce or even eliminate lower lid retraction without any additional lower lid surgery.

Eyelid retraction surgery is required when medical therapy, including topical lubricant drops and ointments, patching, and moisture chambers, is unsuccessful in addressing corneal compromise in TED. In addition, the psychosocial effects of disfigurement secondary to eyelid retraction should not be underestimated.

The standard approach to eyelid retraction surgery is a lid-lengthening procedure. In the upper eyelids, this involves recession of the upper lid retractors. There is rarely (if ever) a need to place a spacer graft in the upper eyelid. In the lower eyelids, surgical repair also includes retractor and conjunctival recession. However, a spacer graft is sometimes required, including ear cartilage graft or an acellular cadaveric graft.

Blepharoplasty, brow lift, and sub-brow fat debulking are all excellent adjunctive cosmetic procedures that can be performed as part of the surgical rehabilitation of patients with TED. Importantly, they should not be combined with eyelid retraction surgery since the additional scarring may undermine the surgical effort to release scar tissue. Eyelid retraction repair should be performed first, and adjunctive cosmetic procedures can be performed once the patient has healed and stability achieved.

Following lid retraction surgery, patients are discharged the same day and instructed to follow up in clinic for re-evaluation within 1 week. An antibiotic or combination antibiotic-steroid ointment is prescribed topically for the surgical wounds. If an underlying corneal epithelial disease is present, the patient should continue ocular surface treatment as per the managing ophthalmologist.

In the event that initial eyelid retraction surgery results in post-operative ptosis or residual retraction, additional surgery may be needed depending on the level of patient satisfaction and functional outcome. In general, it is always easier to address an undercorrected upper eyelid than an eyelid that becomes ptotic following retraction surgery. The fibrosis of the retractors makes ptosis surgery more challenging. Hence, we typically aim for a mild undercorrection rather than overcorrection of upper eyelid retraction. With spacer grafts, lower eyelids typically remain where the surgeons placed them, with good consistency of outcomes.

Surgical management of the of TED begins with careful assessment of the patient and thoughtful planning regarding the timing and approach to surgical rehabilitation. A variety of surgical techniques have been developed to address the functional and cosmetic complications of TED, and these approaches can be tailored to the needs of the individual patient. Traditionally, surgery is performed in a step-wise fashion, first with orbital decompression, followed by strabismus surgery, then lastly, eyelid repositioning. Careful selection of patients for surgery and clear explanation of the limitations and possible complications of surgery will maintain patient satisfaction and maximize successful surgical results.

This is a woman with a history of thyroid eye disease, status post right and left lateral orbital decompression, and finally two staged left upper eyelid retraction repair. Post op at 2 weeks.

This patient with severe thyroid eye disease presented to Dr. Kahana after having had multiple orbital, strabismus and eyelid surgeries over the course of a decade. She was told nothing more could be done. She was suffering from severe exposure, irritation, tearing, double vision, poor vision and facial deformity. She underwent repeat staged orbital decompression surgeries, followed by repeat strabismus and eyelid surgeries. Her eyes are now comfortable, her tearing resolved, and her vision improved, although she still has double vision (tilt), which she treats with prism glasses and monocular occlusion. She is very pleased with the results.

This patient presented with thyroid eye disease and left upper eyelid retraction. She underwent left upper eyelid retraction repair via a posterior approach (no skin incision). Post op is at 6 months.

This patient presented with thyroid eye disease, with proptosis, swelling and eye pain. He underwent bilateral lateral orbital decompression. There was no eyelid surgery performed. Post op is 2 months.

This woman has thyroid eye disease and has had 5 infusions with teprotumumab (Tepezza) with excellent results.


Additional Resources

Orbital Decompression Video Thumbnail
Gaves Disease & Thyroid Foundation Logo